CDMOs: Financial performance H1 2023

EU Commission’s proposed changes to marketing authorisation procedures

Big pharma’s new life without Covid-19 products

Biotech industry: between challenges and optimism

Building a new framework for European pharmaceutical legislation

Artificial intelligence in pharmaceutical development and manufacturing

What potential for biosimilars in healthcare systems?

Medicines: Headed for the Great Shortage?

The Intellectual Property clause in pharmaceutical subcontracting agreements

To repackage or not? Latest CJEU rulings provide guidance for parallel traders of medicines

Protection expiry in Europe: facts and figures

BIO CDMOs: Time for big investments

Nanothechnology in the healthcare

CDMO CEOs: Visions and strategies for 2022 and after

CLINICAL TRIALS ON MEDICINAL PRODUCTS: Overview of the new legal regimes

Boosting the availability of medicines in Europe